Core Viewpoint - Green Leaf Pharmaceutical (02186) reported a revenue of 6.061 billion RMB for the fiscal year ending December 31, 2024, reflecting a year-on-year decrease of 1.33% and a net profit attributable to shareholders of 472 million RMB, down 11.4% from the previous year [1][2] Group 1: Financial Performance - The company's revenue for the reporting period was 6.061 billion RMB, a decrease of 1.33% year-on-year [1] - Net profit attributable to shareholders was 472 million RMB, representing a decline of 11.4% year-on-year [1] - Basic earnings per share were reported at 12.54 cents [1] Group 2: Market Position and Product Portfolio - The company holds a competitive position in four major therapeutic areas in the Chinese market: oncology, central nervous system, cardiovascular, and metabolism [1] - According to IQVIA, oncology, metabolism, central nervous system, and cardiovascular drugs accounted for the first, second, fourth, and fifth largest drug markets in China, respectively [1] - The main product portfolio in China includes six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and one metabolism drug [1] Group 3: Sales Performance by Therapeutic Area - Sales in the central nervous system therapeutic area decreased by 4.8%, totaling 1.613 billion RMB [2] - Sales in the oncology therapeutic area decreased by 1.8%, amounting to 2.085 billion RMB [2] - Sales in the cardiovascular therapeutic area decreased by 1.6%, reaching 1.660 billion RMB [2] - Sales in the metabolism therapeutic area saw a decline of 13.7%, totaling 389 million RMB [2] Group 4: Competitive Advantage - The company's 17 major products have established a strong competitive advantage in global high-prevalence disease areas, with market share expected to grow steadily or maintain current levels [2]